DR-0201
About DR-0201
DR-0201 is a Healthcare company, and was acquired by Sanofi in May 2025. It operates as a bispecific antibodies for B cell cancer treatment are developed. Its chief executive is Paul Hudson. Its focus areas include Life Sciences, Oncology, Drugs and Diversified.
Company details
Immunotherapeutics targeting B cell malignancies are developed by DR-0201 in the biotechnology sector. Bispecific antibodies are offered that bind to phagocytic receptors on myeloid cells and surface receptors on affected B cells. Malignancies addressed include dermatomyositis, lymphoma, and Non-Hodgkin lymphoma, along with related conditions. Operations center on oncology research and therapeutic provision, with leadership under Paul Hudson as CEO.
- SectorsHealthcare
- Acquired by Sanofi (May 2025)
Investors in DR-0201
DR-0201 has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Sanofi.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Pharmaceutical and nutraceutical products are developed across seven therapeutic areas. | 1973 | sanofi.com | Paris, France |
Investor details for DR-0201
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of DR-0201
1 people are tracked at DR-0201 (1 in leadership).
| Name | Role | Group |
|---|---|---|
Paul Hudson | Chief Executive Officer | Leadership |
Complete people profiles for DR-0201
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
10 companies that operate in the same segment as DR-0201 (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 213.52 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about DR-0201
Paul Hudson is the current CEO of DR-0201.
Immunotherapeutics targeting B cell malignancies are developed by DR-0201 in the biotechnology sector. Bispecific antibodies are offered that bind to phagocytic receptors on myeloid cells and surface receptors on affected B cells. Malignancies addressed include dermatomyositis, lymphoma, and Non-Hodgkin lymphoma, along with related conditions. Operations center on oncology research and therapeutic provision, with leadership under Paul Hudson as CEO.
DR-0201 has 1 investor. Key investors include Sanofi.
Yes. DR-0201 was acquired by Sanofi in May 2025.